Cediranib
ASCO: Olaparib and cediranib combo promising for recurrent ovarian cancer
June 05, 2014For women with recurrent platinum-sensitive ovarian cancer, the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib is more effective than olaparib alone.
Cediranib improves survival in recurrent ovarian cancer
October 21, 2013Women with ovarian cancer that has recurred after chemotherapy survived longer after treatment with cediranib, a biological therapy, according to research.
Sign Up for Free e-newsletters
ONA Articles
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- Two Programs, One Goal: Meeting the Challenges of Oncology Navigation
- Navigating Patients with Hematologic Malignancies
- Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer
- Bleeding Disorder Treatments: von Willebrand Disease
- The Caregivers' Cancer Journey
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |